The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

References

• Levy BT, Graber MA. Respiratory syncytial virus infection in infants and young children. J Fam Pract 1997;45:473–81
   PubMed Web of Science ®Google Scholar
• Ottolini MG, Hemming VG. Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery. Drugs 1997;54:867–84
   Google Scholar
• Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847–52
   PubMed Web of Science ®Google Scholar
• Collins CL, Pollard AJ. Respiratory syncytial virus infections in children and adults. J Infect 2002;45:10–17
   PubMed Web of Science ®Google Scholar
• Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98:708–15
   PubMed Web of Science ®Google Scholar
• Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917–28
   PubMed Web of Science ®Google Scholar
• Langley JM, Wang EE, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131:113–7
   PubMed Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143:S150–6
   PubMed Web of Science ®Google Scholar
• Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks’ gestation. Pediatrics 1991;88:527–32
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EA, Hemming VG. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 1995;95:463–7
   Google Scholar
• Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212–9
   PubMed Web of Science ®Google Scholar
• Canadian Paediatric Society. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999;4:474–80
   PubMedGoogle Scholar
• Canadian Paediatric Society. Use of palivizumab in children with congenital heart disease. Paediatr Child Health 2003;8:632–3
   Google Scholar
• National Advisory Committee on Immunization. Statement on the Recommended Use of Monoclonal Anti-RSV Antibody (Palivizumab). Canada Communicable Disease Report Sep 2003;29
   Google Scholar
• IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102:531–7
   Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532–40
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization. Statement on the Recommended Use of Monoclonal Anti-RSV Antibody (Palivizumab). Ottawa 2003
   Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23:815–20
   PubMed Web of Science ®Google Scholar
• Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806–814
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Bont L, Doering G, et al. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis. E-pub Jul16 2008
   PubMed Web of Science ®Google Scholar
• Resch B, Gusenleitner W, Nuijten MJ, et al. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008;30:749–60
   PubMed Web of Science ®Google Scholar
• Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002;156:1034–41
   PubMed Web of Science ®Google Scholar
• Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160:1070–6
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25:55–71
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005
   Google Scholar
• Statistics Canada: Canada's National Statistical Agency. The Daily (2004): Deaths. http://www.statcan.ca/Daily/English/040927/d040927a.htm
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa 2006
   Google Scholar
• Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89:673–8
   PubMed Web of Science ®Google Scholar
• Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541–5
   PubMed Web of Science ®Google Scholar
• Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171:137–41
   PubMed Web of Science ®Google Scholar
• Lanctôt KL, Mitchell I, Paes BA, et al. CARESS: The Canadian Registry of Synagis [abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Research Digest; 2008
   Google Scholar
• Ontario Case Costing Initiative (OCCI). Acute Inpatient Database. http://www.occp.com/
   Google Scholar
• Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85:463–8
   PubMed Web of Science ®Google Scholar
• Health Canada. Ontario Hospital Interprovincial per diem rates for inpatient services (effective July 1, 2004) http://www.health.gov.on.ca/english/providers/program/ohip/bulletins/na_12/na12_att.pdf. Accessed July 16, 2007
   Google Scholar
• Ontario Ministry of Health and Long Term Care. Schedule of Benefits – Physician Services Under the Health Insurance Act (January1, 2007). 2007
   Google Scholar
• Statistics Canada: Canada's National Statistical Agency. Earnings, average weekly, by province and territory (Table); 2007
   Google Scholar
• Statistics Canada: Canada's National Statistical Agency. The Daily: Labour Force Survey. http://www.statcan.ca/Daily/English/071207/d071207a.htm
   Google Scholar
• Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419–27
   PubMed Web of Science ®Google Scholar
• Furlong WJ, Feeny DH, Torrance GW, et al. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375–84
   PubMed Web of Science ®Google Scholar
• Chiou CF, Weaver MR, Bell MA, et al. Development of the multi-attribute Pediatric Asthma Health Outcome Measure (PAHOM). Int J Qual Health Care 2005;17:23–30
   PubMed Web of Science ®Google Scholar
• Ontario Nursing Association (ONA). Full-time RN Hourly Rate Ranges. http://ona.org/faq#f17
   Google Scholar
• Wills S, Simpson JH, Coutts J. Cost minimisation of RSV prevention with palivizumab. Arch Dis Child 2006;91:717
   PubMed Web of Science ®Google Scholar
• Gooding J, Millage A, Rye A-K, et al. The cost and safety of multidose use of palivizumab vials. Clin Pediatr 2008;47:160–3. Epub 2007 Sep 27
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher MJ, Claxton K. Decision Modelling for Health Economic Evaluation: Oxford University Press, 2006
   Google Scholar
• Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471–80
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Live births, weeks of gestation indicators. http://cansim2.statcan.ca/. Accessed July 16, 2007
   Google Scholar
• Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473–81
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drug and Technology in Health (CADTH). Common Drug Review Database. Available at: http://www.cadth.ca/index.php/en/cdr/search?&status=complete&order_field=drug_name. Accessed July 31, 2007
   Google Scholar
• Lazaro y de Mercado P, Figueras Aloy J, Domenech Martinez E, et al. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain]. An Pediatr (Barc) 2006;65:316–24
   PubMedGoogle Scholar
• Figueras Aloy J, Quero J, Domenech E, et al. [Recommendations for the prevention of respiratory syncytial virus infection]. An Pediatr (Barc) 2005;63:357–62
   PubMedGoogle Scholar
• American Academy of PediatricsRevised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442–6
   PubMed Web of Science ®Google Scholar
• Strutton DR, Stang PE. Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: Economic-based decision-making. J Pediatr 2003;143:S157–62
   Web of Science ®Google Scholar
• Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606–11
   PubMed Web of Science ®Google Scholar
• Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007;151:34–42, 42 e31
   PubMed Web of Science ®Google Scholar
• Health Canada. Ontario Hospital Interprovincial per diem rates for inpatient services (effective July 1, 2004). http://www.health.gov.on.ca/english/providers/program/ohip/bulletins/na_12/na12_att.pdf
   Google Scholar